Prosthetic Heart Valve Market to Surpass US$ 21,968.6 Million by 2027 - Coherent Market Insights

Posted September 17, 2021 by SANJAYCMI

Global Prosthetic Heart Valves Market

In general, bioprosthetic valves are composed of animal tissues that are mounted on a metal or polymer support. These valves are harvested from the cow heart sac (bovine) or porcine (pig’s) heart valves. The less invasive procedure to replace the damaged aortic valve with bioprosthetic aortic valve is the percutaneous aortic valve replacement (PAVR). Transcatheter mitral valve repair is a minimally invasive procedure for the treatment of degenerative mitral regurgitation (MR) disorder, mostly affecting the ageing population.

The global prosthetic heart valves market is estimated to garner up to US$ 21,968.6 million, in terms of value, by the end of 2027.

Increasing heart valve implantation procedures to bolster the global market expansion

Rising number of heart valve implantation procedures being performed globally is expected to propel the growth of the global prosthetic heart valves market over the forecast period. For instance, in the study titled ‘Annual number of candidates for transcatheter aortic valve implantation per country: current estimates and future projections’, published in the European Heart Journal in July 2018, it was estimated that 114,757 and 58,556 candidates get transcatheter aortic valve implantation done in Europe and Northern America respectively, each year.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report:

Mechanical heart valves are the most commonly used prosthetic heart valves in the treatment of patients with a valvular heart disease. These valves are highly durable and bring out favorable outcomes on usage, as compared to tissue heart valves. However, tissue heart valves are more preferable for the treatment of geriatric patients, as these are accepted much faster by the body. Therefore, numerous companies are working on the improvement of tissue heart valve (bioprosthetic valve) implantation products, in order to expand their lifespan, and thus increase their adoption.

In contrast, increasing product recalls is predicted to hamper the growth of the global prosthetic heart valves market in the near future. For instance, in August 2019, Edwards Lifesciences recalled its Sapien 3 Ultra replacement heart valve amid risk of bursting of balloons during the implantation of the transcatheter aortic valve.

Key Market Takeaways

The biological/tissue heart valves segment held the foremost position in the global prosthetic heart valves market in 2019, accounting for an impressive 42.0% share, in terms of value. Increasing heart valve implantation procedures is expected to fuel the demand for prosthetic heart valves over the forecast timeframe.

Moreover, the transcatheter heart valves segment in the global prosthetic heart valves market was valued at US$ 2,572.8 million in 2019 and is expected to reach US$ 6,874.8 million over the projected period, displaying a CAGR of 13.1%. Burgeoning prevalence of valvular heart disease (VHD) is poised to drive the segmental growth in the upcoming years.

Browse Research Report:

The prevalence rate of congenital heart disease has been found to be high among children, especially in the developing nations, which in turn, fosters the demand for prosthetic heart valves worldwide. According to a study, titled ‘Prevalence, profile, and pattern of congenital heart disease in Central India: A prospective, observational study’, published in May 2018, the prevalence rate of congenital heart disease was valued at 10.13/1000 live births.

Competitive Landscape

The major players operating in the global prosthetic heart valves market include Edwards Lifesciences Corporation, Medtronic Plc, Boston Scientific Corporation, Abbott Laboratories, LivaNova PLC, CryoLife, Inc., Braile Biomedica, Colibri Heart Valve, LLC, and JenaValve Technology, Inc.

Key Developments

In September 2019, Medtronic Plc launched the Evolut PRO+ TAVR System, which is a new-generation TAVR system intended for the treatment of patients with symptomatic severe aortic stenosis, who are at a low risk of surgical mortality. Furthermroe, in February 2019, LivaNova PLC received reimbursement for its Perceval sutureless aortic heart valve in Japan from the Ministry of Health, Labor and Welfare, for the treatment of the aortic valve disease.

Buy-Now this research report:

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Coherent Market Insights
Phone +1-206-701-6702
Business Address 1001 4th Ave
# 3200 Seattle, WA 98154, U.S.
Country United States
Categories Health , Marketing , Research
Tags prosthetic heart valve market , prosthetic heart valve market share , prosthetic heart valve market size
Last Updated September 17, 2021